{"id":53034,"date":"2025-08-18T07:18:45","date_gmt":"2025-08-18T07:18:45","guid":{"rendered":"https:\/\/volity.io\/blog\/changamoto-za-hati-miliki-na-athari-za-ai-katika-sekta-ya-dawa-na-bima\/"},"modified":"2026-09-08T23:50:26","modified_gmt":"2026-09-08T23:50:26","slug":"big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake","status":"publish","type":"post","link":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","title":{"rendered":"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima"},"content":{"rendered":"\n    <style>\n    .vd-wrap {\n        display: flex;\n        align-items: flex-start;\n        gap: 20px;\n        background: #ffffff;\n        border: 1px solid #f2f4f7;\n        border-left: 4px solid #c0392b;\n        border-radius: 12px;\n        padding: 24px;\n        margin: 30px 0;\n        box-sizing: border-box;\n        width: 100%;\n        box-shadow: 0 4px 20px rgba(0,0,0,0.04);\n        position: relative;\n        overflow: hidden;\n    }\n    .vd-wrap::after {\n        content: \"\";\n        position: absolute;\n        right: -20px;\n        bottom: -20px;\n        width: 100px;\n        height: 100px;\n        background: radial-gradient(circle, rgba(192, 57, 43, 0.03) 0%, transparent 70%);\n        pointer-events: none;\n    }\n    .vd-icon {\n        flex-shrink: 0;\n        background: #fff5f4;\n        border: 1px solid #fee2e1;\n        border-radius: 8px;\n        width: 40px;\n        height: 40px;\n        display: flex;\n        align-items: center;\n        justify-content: center;\n    }\n    .vd-icon svg { width: 22px; height: 22px; }\n    .vd-content { flex: 1; min-width: 0; }\n    .vd-label {\n        display: block;\n        font-size: 11px;\n        font-weight: 800;\n        letter-spacing: 0.1em;\n        text-transform: uppercase;\n        color: #c0392b;\n        margin-bottom: 8px;\n        font-family: \"Inter\", sans-serif;\n    }\n    .vd-text {\n        font-size: 14px;\n        line-height: 1.6;\n        color: #475467;\n        margin: 0;\n        font-family: \"Inter\", sans-serif;\n    }\n    .vd-text p { margin: 0 0 10px 0; }\n    .vd-text p:last-child { margin-bottom: 0; }\n    .vd-text strong { color: #101828; font-weight: 600; }\n    .vd-text a { color: #c0392b; text-decoration: underline; }\n    @media (max-width: 600px) {\n        .vd-wrap { flex-direction: column; gap: 12px; padding: 20px; }\n        .vd-icon { width: 32px; height: 32px; }\n    }\n    <\/style>\n\n    <div class=\"vd-wrap\" role=\"alert\" aria-label=\"Ufichuzi wa hatari\">\n        <div class=\"vd-icon\">\n            <svg viewBox=\"0 0 24 24\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                <path d=\"M12 9V14M12 17.01L12.01 16.998M12 21C16.9706 21 21 16.9706 21 12C21 7.02944 16.9706 3 12 3C7.02944 3 3 7.02944 3 12C3 16.9706 7.02944 21 12 21Z\" stroke=\"#c0392b\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/>\n            <\/svg>\n        <\/div>\n        <div class=\"vd-content\">\n            <span class=\"vd-label\">Ufichuzi wa Hatari wa Kidhibiti<\/span>\n            <div class=\"vd-text\"><p>Kuwekeza katika bidhaa za kifedha kunahusisha hatari. Hasara zinaweza kuzidi thamani ya uwekezaji wako wa awali.<\/p><\/div>\n        <\/div>\n    <\/div>\n\r\n\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Kuna mdundo wa kimya unaoendelea chini ya uso wa sekta ya dawa, na unazidi kusikika kwa nguvu. Zaidi ya nusu trilioni ya USD katika mauzo ya dawa kubwa zinakaribia ukingo wa hati miliki. Huku ulinzi huo ukififia, kampuni kubwa za dawa zinakabiliwa na uhalisia ambao unaweza kubadilisha kila kitu kuanzia uwezo wa kupanga bei hadi njia za utengenezaji.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-patents-are-expiring-and-fast\">Hatimiliki Zinaisha Muda Wake &#8211; na kwa Kasi<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Dawa kama Keytruda (Merck), Eliquis (Pfizer), na Humira pamoja na Rinvoq (AbbVie) zote ziko hatarini. Ulinzi wa hataza zao unatarajiwa kuisha kati ya mwaka 2027 na 2036. Hizi si tiba za kawaida, bali ni vyanzo vikubwa vya mapato. Kwa kampuni ya AbbVie, dawa mbili pekee kati ya hizo zilichangia karibu nusu ya mapato yake mwaka 2024.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hati miliki hizo zitakapokwisha muda wake, matoleo ya generic na biosimilar yako tayari kuingia sokoni na kupunguza kwa kiasi kikubwa faida za makampuni makubwa ya dawa.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-tangled-webs-of-patents-now-under-fire\">Utata wa Hati Miliki &#8211; Sasa Uko Chini ya Shinikizo<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Kwa miaka mingi, watengenezaji wa dawa walitumia &#8220;patent thickets&#8221; kuzuia washindani. Kwa kuwasilisha hati miliki nyingi, hata mamia, zinazopishana &#8211; wakati mwingine baada ya idhini ya FDA &#8211; walijenga ngome za kisheria kuzunguka bidhaa moja moja.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Lakini utafiti wa JAMA wa mwaka 2024 ulibaini kuwa 75% ya hataza hizo hazikuwa na uhusiano mkubwa na viambato amilifu, bali zilikuwa ni mbinu za kisheria tu. Na sasa, Washington inachukua hatua kali. Mnamo mwaka 2025, wabunge walisukuma mbele miswada inayolenga kupunguza idadi ya hataza zinazoweza kutumiwa kama silaha mahakamani. Ikiwa itapitishwa, inaweza kufupisha kwa kiasi kikubwa muda ambao watengenezaji wa dawa wanaweza kuwazuia washindani wao.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-cash-rich-but-nowhere-to-spend\">Je, una pesa nyingi, lakini huna pa kuzitumia?<\/h2><p class=\"wp-block-paragraph\">Kwa muktadha wa uwekezaji wa hisa katika sekta mahususi, angalia <a href=\"https:\/\/volity.io\/stocks\/stock-market-sectors\/\">stock market sectors<\/a>, <a href=\"https:\/\/volity.io\/stocks\/blue-chip-stocks\/\">blue chip stocks<\/a>, na <a href=\"https:\/\/volity.io\/stocks\/fundamental-analysis\/\">fundamental analysis<\/a>.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Mifuko ya makampuni ya dawa ina fedha nyingi, nyingi sana. Kwa uwezo wa zaidi ya $700 billion katika shughuli za M&amp;A uliotayari kutumika, unaweza kudhani kuwa wimbi lijalo la mikataba ya biotech litakuwa likistawi. Isipokuwa&#8230; kuna changamoto.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Lengo bora la ununuzi &#8211; makampuni ya bioteknolojia yenye mapato halisi na siyo tu &#8220;majaribio ya kisayansi&#8221; &#8211; ni adimu. Na mikataba inapotokea, haifanyi kazi kila wakati. Tangu 2018, karibu 80% ya IPO za bioteknolojia zimefeli, na kufuta mabilioni ya mtaji wa wawekezaji na kuwaacha timu za M&amp;A wakiwa na hofu.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-a-policy-storm-is-brewing\">Dhoruba ya Sera Inakaribia<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Sio tu hataza. Pendekezo jipya linaweza kuweka kodi ya 1-5% ya IP kwenye hataza za bioteknolojia &#8211; mabadiliko makubwa kutoka kwa mfumo wa sasa wa viwango bapa. Mabadiliko haya yataathiri jinsi makampuni (na wawekezaji) wanavyothamini miliki ya ubunifu, na jinsi wanavyofuatilia R&amp;D kwa bidii.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hata taasisi za kitaaluma za hadhi ya juu ziko chini ya uangalizi. Harvard, inayomiliki hataza zaidi ya 58,000 na mamia ya mikataba ya leseni, sasa inakabiliwa na uchunguzi wa serikali kuu kwa madai ya mapungufu katika ufichuzi wa utafiti unaofadhiliwa na serikali. Ikiwa uchunguzi huo utasababisha vikwazo, mfumo mzima wa uvumbuzi kutoka vyuo vikuu kwenda viwandani unaweza kutikisika.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-so-what-happens-next\">Basi, nini kinafuata?<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Ili kukabiliana na mabadiliko haya, kampuni kubwa za dawa zinapaswa kusawazisha matakwa matatu magumu:<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>Dumisha ubunifu &#8211; kupitia utafiti na maendeleo ya ndani pamoja na mikataba ya nje;<\/li>\r\n\r\n\r\n\r\n<li>Linda hazina zao za hataza &#8211; bila kusababisha mizozo ya kisheria au kisiasa;<\/li>\r\n\r\n\r\n\r\n<li>Tumia mtaji kwa busara &#8211; katika soko ambalo halitoi tena zawadi kwa ajili ya hype.<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Tathmini za thamani zinaweza kuonekana kuwa nafuu, lakini wawekezaji tahadharini: baadhi ya hisa hizi ziko kwenye mchanga unaotiririka. Mteremko wa hataza si tukio la kalenda tu &#8211; ni ramani ya nani aliye hatarini, nani anayetaabika kutafuta ukuaji mpya, na nani anayejenga uthabiti kimya kimya.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-algorithms-vs-patients-how-ai-in-insurance-is-rewriting-healthcare\">Algorithms dhidi ya Wagonjwa: Jinsi AI katika Bima Inavyobadilisha Huduma za Afya<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">AI ilitakiwa kuleta mapinduzi katika sekta ya afya, na kwa namna fulani, imefanya hivyo. Lakini mapinduzi si mara zote huwa nadhifu. Kimya kimya, makampuni ya bima yameanzisha matumizi ya artificial intelligence si kwa ajili ya kutibu, bali kwa ajili ya kupunguza gharama. Hii inazidi kumaanisha neno moja tu kwa wagonjwa: &#8220;hapana.&#8221;<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-denials-at-machine-speed\">Kukataliwa kwa Kasi ya Mashine<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hapa ndipo kiini cha tatizo: kampuni nyingi za bima sasa hutumia mifumo ya AI kufanya idhini za awali &#8211; yaani ule utaratibu wa &#8220;je, tutagharamia hili?&#8221;. Na jambo la kusikitisha ni kwamba: zana hizi hazipendekezi matibabu, bali zinayakataa.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Katika kisa kimoja mashuhuri, mfumo wa PXDX wa kampuni ya bima ulichakata zaidi ya madai 300,000 ndani ya miezi miwili. Madaktari walikagua faili hizo kwa kasi ya sekunde 1.2 kila moja. Huo si uamuzi wa kimatibabu, hiyo ni otomatiki inayofanya kazi kwa kasi ya ajabu.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Jaribu kukata rufaa? Nafasi ni finyu. Chini ya 0.2% ya maombi yaliyokataliwa katika mipango ya soko ya ACA hukatiwa rufaa, na sehemu ndogo zaidi hufanikiwa.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-black-boxes-thin-oversight\">Black Boxes, Usimamizi hafifu<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Algorithm hizi hazidhibitiwi kama dawa au vifaa vya matibabu. Ni mali binafsi na haziko wazi. FDA haizishughulikii. Hakuna uwazi unaohitajika, hakuna kiwango cha kawaida cha haki, na hakuna uhakika kwamba upendeleo umeondolewa.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Na madhara haya si ya kubuni tu. Madaktari wanaripoti wagonjwa kuacha matibabu baada ya maombi yao kukataliwa. Inakadiriwa kuwa 94% wanasema kuwa idhini ya awali huchelewesha matibabu yanayohitajika; mmoja kati ya wanne ameshuhudia madhara makubwa yanayotokana na ucheleweshaji huo.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-the-slow-pushback\">Upinzani wa Polepole<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Ndiyo, kuna kelele nyingi. Zaidi ya kampuni 50 za bima zimeahidi kurahisisha idhini ya awali &#8211; vizuizi vichache, kanuni zilizo wazi zaidi. Sekta hii imewahi kutoa ahadi kama hizi hapo awali.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Wakati huo huo, sheria ya No Surprises Act ilibadilisha mazingira ya ushindani. Watoa huduma waliwasilisha takriban migogoro milioni 1.5 mwaka 2024, idadi ambayo ni kubwa zaidi kuliko ilivyotabiriwa. Gharama za kiutawala za pambano hilo? Zaidi ya $300 million.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-when-algorithms-get-overruled\">Wakati Algorithmu Zinapobatilishwa<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hapa ndipo penye utata: pale maamuzi haya ya kukataa madai yanayoendeshwa na AI yanapopingwa na wanasheria &#8211; si wagonjwa &#8211; mara nyingi huanguka. Mfumo wa kampuni kubwa ya bima, nHPredict, ulishuhudia takriban 90% ya maamuzi yake yakibatilishwa na majaji wa shirikisho. Hilo linaashiria zaidi ya makosa tu; linaashiria mchakato uliovunjika.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hata hivyo, rufaa huchukua muda. Miezi, wakati mwingine miaka. Wagonjwa wengi hawana muda huo wa kusubiri. Wengine hufariki kabla ya kuona uamuzi ukibatilishwa.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-can-ai-be-trusted-with-care-decisions\">Je, AI inaweza kuaminiwa katika maamuzi ya utunzaji?<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">AI inaweza kurahisisha makaratasi na kubaini makosa. Lakini algoriti zinapoamua matibabu bila usimamizi wa kweli wa binadamu, hali inakuwa hatari. Uwajibikaji unakosekana. Udhibiti unasalia nyuma. Na wagonjwa wamenaswa katika mfumo ambao umeboreshwa zaidi kwa ajili ya akiba kuliko kwa ajili ya afya.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-who-pays-for-science-the-political-fight-for-america-s-research-future\">Nani Anagharamia Sayansi? Mapambano ya Kisiasa Kuhusu Mustakabali wa Utafiti wa Marekani<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Sayansi haipaswi kuwa nyenzo ya kampeni, lakini ndivyo ilivyo sasa. Mnamo mwaka 2025, taasisi zinazosimamia uhariri wa jeni, chanjo za janga, na miongo kadhaa ya mafanikio ya kibayomedali zinavutwa katika migogoro ya bajeti na vita vya kifikra.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-public-science-on-the-chopping-block\">Sayansi ya Umma Ipo Hatarini<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">NIH. CDC. NSF. BARDA. Hapo awali zilikuwa vito vya thamani vya utafiti nchini Marekani. Mwaka huu, kila moja imepata pigo &#8211; baadhi zikiwa na pigo zito. BARDA pekee ilisitisha miradi 22 ya ushirikiano wa umma na sekta binafsi mnamo 2025, wakala huohuo uliosaidia kuharakisha chanjo za mRNA kutoka maabara hadi kliniki.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Katika FDA, mabadiliko ya uongozi yanaonekana kama mlango unaozunguka. Na kamati ya ushauri ya chanjo ya CDC? Iliwekwa kando kwa mpigo mmoja na RFK Jr. Sio suala la $ tena; ni suala la nani anayeshikilia usukani.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-what-happens-when-you-defund-discovery\">Nini Hutokea Unapositisha Ufadhili wa Discovery?<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Nyufa zinaonekana haraka. Mlipuko wa surua ndio mbaya zaidi katika kipindi cha zaidi ya miaka thelathini. Kusita kupata chanjo kumerudi kwenye kurasa za mbele. Miradi ya bioteknolojia inasuasua, si kwa sababu ya kukosa mawazo, bali kwa sababu ya kukosa ruzuku ya kuyaendeleza.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hata taasisi kubwa za kitaaluma hazijakingwa. Harvard &#8211; ndiyo, Harvard hiyo &#8211; inachunguzwa na serikali kuhusu jinsi utafiti unaofadhiliwa na serikali unavyogeuzwa kuwa hataza. Ikiwa wadhibiti watachukua hatua kali, daraja kati ya chuo kikuu na sekta ya viwanda linaweza kuyumba, na labda kuvunjika.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-the-private-sector-can-t-do-it-alone\">Sekta Binafsi Haiwezi Kufanya Haya Pekee<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hapa kuna ukweli mchungu: mtaji wa kibinafsi mara chache hufadhili hatua za awali na zenye utata za uvumbuzi. Husubiri hadi hatari ipunguzwe. mRNA? Hiyo ilichukua miongo kadhaa ya msaada wa umma kabla ya pesa za venture kufika.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Kata safu hiyo ya msingi sasa, na hutapunguza kasi ya sayansi pekee &#8211; unafuta mustakabali ambao haupata nafasi ya kuwepo.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-why-are-we-doing-this\">Kwa nini tunafanya hivi?<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Siasa, zaidi. Sayansi haina kundi la wapiga kura, haina ushindi wa haraka. Ni polepole, ya kiufundi, wakati mwingine inakera &#8211; na ni ghali. Bajeti zinapopunguzwa, utafiti mara nyingi ndio wa kwanza kuathirika.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-what-s-at-stake-is-resilience\">Kinachozingatiwa Hapa Ni Volity<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Uwezo wa kukabiliana na virusi vijavyo, kushindwa kwa dawa za antibiotiki kijacho, na jambo lolote lisilojulikana. Tukiharibu mfumo huu wa ikolojia, tutakuwa tukisafiri bila vyombo vya kuongozea.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-a-call-for-recommitment\">Wito wa Kujitolea Upya<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Ikiwa Marekani inataka kuongoza katika sayansi ya maisha, inahitaji zaidi ya maabara bora &#8211; inahitaji utashi wa kisiasa. Tenga bajeti za utafiti mbali na mizunguko ya uchaguzi. Ichukulie NIH na taasisi nyingine kama mali za kimkakati, si kama vitu vya kuchezea.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Wawekezaji, viongozi wa afya, na wapiga kura wote wana maslahi katika jambo hili. Ufadhili si kipengele cha bajeti pekee, bali ni tamko la maadili kuhusu mustakabali tutakaokuwa nao.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-why-you-re-getting-sicker-the-quiet-collapse-of-american-healthcare-access\">Kwa Nini Unazidi Kuugua: Kuporomoka Kimya Kimya kwa Upatikanaji wa Huduma za Afya nchini Marekani<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Huu si virusi vipya, wala si upungufu wa teknolojia. Ni jambo la kawaida zaidi, la kimfumo. Matokeo ya afya nchini U.S. yanashuka, na mhusika mkuu si dawa bali ni njia ya kuzipata. Mnamo 2025, njia hiyo inaanza kupasuka.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-shrinking-coverage-rising-costs\">Volity Inayopungua, Gharama Zinazopanda<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Anza na mambo ya msingi. Usajili wa Medicaid umepungua &#8211; zaidi ya watu milioni 10 wameondolewa baada ya ulinzi wa janga kumalizika, wengi wao kutokana na makosa ya makaratasi ambayo yangeweza kurekebishwa kwa kupiga simu&#8230; isipokuwa kituo cha kupokea simu kimejaa na muda wa mwisho umepita.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Wakati huo huo, mipango ya waajiri inagharimu zaidi na kutoa huduma kidogo. Gharama za ziada zinapanda. Viwango vya juu vya malipo ya mfukoni vinazidi kuwa mzigo. Kuwa na &#8220;bima&#8221; mara nyingi inamaanisha kulipa ada ya juu kwa ajili ya fursa ya kuendelea kuwa katika hatari.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-it-s-not-just-you-it-s-the-system\">Sio Wewe Pekee, Ni Mfumo<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Kote duniani, watu wanajali kidogo zaidi &#8211; si kwa sababu wamekuwa na afya njema ghafla, bali kwa sababu wanaogopa gharama za matibabu. Uchunguzi wa afya unapungua. Ziara za kuzuia magonjwa zinaahirishwa. Hali za kiafya zinazidi kuwa mbaya hadi zinapogeuka kuwa dharura kubwa.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hata hivyo, injini ya faida ya sekta hii inaendelea kunguruma: EBITDA ya huduma za afya inatarajiwa kukua kwa zaidi ya $300B ifikapo mwaka 2028. Mfumo huu unajipatia mapato zaidi hata wakati wagonjwa wakipokea huduma kidogo.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-the-ai-denial-machine\">Mfumo wa AI wa Kukataa Ukweli<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Ili kuongeza chumvi kwenye kidonda, AI sasa imekuwa mlinzi wa siri. Makampuni ya bima yanatumia zana za kiotomatiki za uidhinishaji wa awali na madai ambazo hukataa maombi kwa wingi. Baadhi ya matibabu ya kuokoa maisha huwekewa alama ya &#8220;hapana&#8221; kama chaguo-msingi. Rufaa zipo kwenye karatasi; kwa uhalisia, ni nadra, ni za polepole, na ni zenye kuumiza.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Je, ni bora? Sana. Je, inaleta faida? Ndiyo. Lakini inawaondoa watu kwenye njia sahihi ya utunzaji.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-winners-and-losers\">Washindi na Walioshindwa<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Mgawanyiko unazidi kuwa mkubwa. Wagonjwa wenye uwezo bado wanapata nafasi za huduma za kipekee, dawa za majaribio, na hata upasuaji nje ya nchi ikihitajika. Wengine wote wanahangaika na mitandao inayopungua, bili za ghafla, na ucheleweshaji mrefu.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hili si tatizo la uwezo wa kifedha tu; ni hitilafu ya kimfumo, ambapo mfumo tajiri zaidi wa huduma za afya duniani unatatizika kutoa huduma za msingi kwa mamilioni ya watu.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-the-real-cost\">Gharama Halisi<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Upatikanaji unapopungua, matatizo makubwa hufuata. Magonjwa sugu hayapatiwi matibabu. Afya ya akili inazorota. Muda wa kuishi unapungua &#8211; kwa miaka mitatu mfululizo nchini U.S., hivi karibuni. Uzalishaji unashuka, uvumbuzi unapungua, na ukosefu wa usawa unazidi kuota mizizi.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Kwa hivyo ndiyo, Wamarekani wanazidi kuwa wagonjwa. Na hapana, hiyo si bahati mbaya &#8211; ni sera, mchakato, na usanifu.<\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\" id=\"h-5-trading-and-investment-ideas\"><strong>Mawazo 5 ya trading na uwekezaji<\/strong><\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Hizi hapa ni <strong>fikra 5 za trading na uwekezaji<\/strong> zilizochochewa moja kwa moja na maarifa kutoka kwa makala haya &#8211; zikijumuisha sekta ya dawa, bioteknolojia, hatari za sera za afya, na uwekezaji wa muda mrefu katika uvumbuzi:<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>1. Long: Kampuni kubwa za dawa zilizouzwa kupita kiasi (Deep Value Play)<\/strong><\/h3>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Mifano:<\/strong> Merck (MRK), Bristol Myers Squibb (BMY), AbbVie (ABBV)<br><strong>Kwa nini:<\/strong> Trading kwa 8-10\u00d7 ya mapato ya baadaye &#8211; karibu na viwango vya kihistoria vya mgogoro &#8211; licha ya miradi imara na usaidizi wa gawio. Changamoto ya hataza ni ya kweli, lakini imezingatiwa kwa kiasi kikubwa kwenye bei. Fuatilia uwezekano wa kupanda kwa bei huku wawekezaji wakielekeza umakini wao kwenye misingi ya biashara.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Kichocheo:<\/strong> Maelewano ya kisheria kuhusu mageuzi ya IP; mikataba ya kushtukiza ya M&amp;A; matokeo ya utafiti wa dawa.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>2. Short: Makampuni ya Bima ya Afya Yanayotegemea AI (Mkakati wa Hatari ya Sera)<\/strong><\/h3>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Mifano:<\/strong> UnitedHealth (UNH), Cigna (CI), Elevance Health (ELV)<br><strong>Kwa nini:<\/strong> Zana za idhini ya awali zinazotumia AI zinakabiliwa na uchunguzi wa kisheria na uwezekano wa kesi mahakamani. Mifano ya faida inayotegemea kukataa huduma inaweza kuwa isiyo endelevu. Shinikizo la kisheria na malalamiko kutoka kwa wagonjwa yanaweza kupunguza faida.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Kichocheo:<\/strong> Uingiliaji kati wa serikali kuu, kesi za pamoja za kisheria, upanuzi wa utekelezaji wa No Surprises Act.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>3. Long: ETF za Miundombinu ya Sayansi na Mashirika ya Utafiti wa Mikataba<\/strong><\/h3>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Mifano:<\/strong> IBB, XBI (ETF za bioteknolojia); Thermo Fisher (TMO), Charles River Labs (CRL)<br><strong>Kwa nini:<\/strong> Kupunguzwa kwa bajeti ya umma katika sayansi kunatoa nafasi kwa makampuni binafsi ya R&amp;D. Ikiwa bajeti za NIH\/NFS zitapungua, CRO na watengenezaji wa zana wanaweza kufaidika kutokana na uvumbuzi unaotolewa kwa wakandarasi wa nje.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Kichocheo:<\/strong> Mabadiliko katika ugawaji wa bajeti ya serikali kuu; kuongezeka kwa ufadhili wa utafiti katika sekta binafsi.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>4. Mkakati wa Matukio: Malengo ya M&amp;A katika Sekta ya Biotech<\/strong><\/h3>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Vigezo:<\/strong> Kampuni za bioteknolojia za Awamu ya III zinazozalisha mapato na zenye hatari ndogo, ambazo thamani yake imeshuka baada ya IPO.<br><strong>Vichungi:<\/strong> Tafuta kampuni zenye thamani ya chini ya $5B zilizo na pesa taslimu mkononi na miradi ya hatua za mwisho katika nyanja za oncology, immunology, au CNS.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Kwa nini:<\/strong> Makampuni makubwa ya dawa yana zaidi ya $700B ya mtaji lakini yanatatizika kupata malengo yanayofaa. Wakati mkwamo huu utakapovunjika, ununuzi wa makampuni utakuwa wa haraka na wa faida kubwa.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h3 class=\"wp-block-heading\">\ud83d\udca1 <strong>5. Mada ya Muda Mrefu: Upatikanaji wa Afya Ulimwenguni + Afya ya Kidijitali<\/strong><\/h3>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Mifano:<\/strong> Teladoc (TDOC), Doximity (DOCS), Philips (PHG); minyororo ya hospitali katika masoko yanayoibukia<br><strong>Kwa nini:<\/strong> Kupungua kwa kimuundo kwa upatikanaji wa huduma nchini Marekani kunatoa msukumo kwa mifumo mbadala. Mahitaji ya kimataifa ya huduma za afya za kidijitali na nafuu yanaongezeka. Nchi zilizo nje ya Marekani zinaweza kuruka hatua za mifumo iliyofeli.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><strong>Kichocheo:<\/strong> Uwekezaji wa kimataifa katika afya, mifumo ya AI-healthcare, na kupitishwa kwa teknolojia katika masoko yanayoendelea.<\/p>\r\n\r\n\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\">Volity: Mahali Ambapo Kiasi Chochote Kinapata Uepesi<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">Katika Volity, tunaamini kuwa afya na fedha vina uhusiano. Watu wanaposhindwa kupata huduma, hawawezi kunufaika na fursa. Ndiyo maana tunaunga mkono masoko ya wazi na kufanya maamuzi kwa kuzingatia taarifa sahihi.<br><strong>Pata faida yako ya kipekee katika <a href=\"https:\/\/volity.io\/sw\/\">volity.io<\/a>.<\/strong><\/p>\r\n<div class=\"quick-answer\" data-volity-unique=\"1\" style=\"background:#f7f7f7;border-left:4px solid #0066cc;padding:12px 16px;margin:16px 0;\"><strong>Jibu la haraka:<\/strong> Kampuni kubwa za dawa zipo katikati ya mzunguko wa kimuundo wa kumalizika kwa hati miliki kuanzia 2027-2030, ambao utaona takriban $200 bilioni za mapato ya dawa zenye chapa zikikabiliwa na ushindani kutoka kwa dawa zinazofanana na zile za asili (biosimilar) na dawa za kawaida (generic), huku mizunguko ya mazungumzo ya bei ya Medicare chini ya Sheria ya Kupunguza Mfumuko wa Bei ikiongeza shinikizo la pili la faida kwenye soko la Marekani. Mwaka 2026 unatawaliwa na biashara ya dawa za unene na kisukari za GLP-1 (Eli Lilly na Novo Nordisk), kumalizika kwa muda wa kipekee wa Keytruda kwa Merck, na mazingira ya baada ya Humira ya biosimilar yanayofafanua upya jinsi uzinduzi wa dawa za kibiolojia zenye chapa unavyopangiwa bei. Biashara hii siyo tena &#8220;pharma ni ya kujilinda&#8221;; biashara sasa ni kuhusu uwezo wa kila hisa kujaza mirija ya bidhaa mpya dhidi ya hatari ya kuporomoka kwa mapato.<p style=\"margin:8px 0 0;\"><em>Na Alexander Bennett, dawati la utafiti la Volity.<\/em><\/p><\/div><p><strong>Mambo ambayo wachambuzi wetu huangalia:<\/strong> Usomaji wa mambo matatu huimarisha mtazamo makini wa hisa za dawa ambao huchuja simulizi zenye kelele nyingi. Uwiano wa kujaza mirija ya bidhaa, unaopimwa kama thamani ya sasa ya mali za Awamu ya III na hatua za usajili dhidi ya thamani ya sasa ya mapato yaliyo hatarini kwa kumalizika kwa hati miliki ndani ya miezi 60 ijayo, hutenganisha kampuni zilizolindwa kimuundo na hatari ya kuyeyuka kwa mzunguko wa mwisho. Kasi ya idhini ya FDA Center for Drug Evaluation and Research dhidi ya wastani wa kihistoria huashiria mahali ambapo utendaji wa kikanuni unaunga mkono au kuzuia kasi ya uzinduzi mpya. Na hatari ya mazungumzo ya Medicare IRA (orodha iliyochapishwa ya dawa zilizojadiliwa na CMS na kundi lililopangwa kwa mizunguko ijayo ya mazungumzo) huonyesha ni kampuni zipi za Marekani zitakazokabiliwa na shinikizo la bei zilizodhibitiwa na kwa muda gani. Mchanganyiko huu huchuja sehemu kubwa ya kelele zinazoletwa na maoni ya EPS ya kila robo mwaka.<\/p><hr><h2 id=\"faq\" data-volity-unique=\"1\">Maswali yanayoulizwa mara kwa mara<\/h2><h3>Je, ukubwa wa changamoto ya hataza ya 2026-2030 ni upi kwa thamani ya dola?<\/h3><p>Makubaliano ya sekta yanaweka mapato ya dawa zenye chapa yaliyo hatarini kupoteza upekee katika takriban $200 bilioni katika kipindi cha 2026-2030, huku dawa za kibiolojia zikichukua sehemu kubwa zaidi kuliko katika mizunguko ya awali ya changamoto hii. Kituo cha uidhinishaji wa dawa na hifadhidata cha FDA huchapisha orodha za marejeleo za Orange Book na Purple Book ambazo madawati ya kitaasisi hulinganisha na kalenda za upekee zilizotolewa na kampuni. Mtazamo wa kimuundo kwa wawekezaji ni huu: hatari ya changamoto hii imejikita zaidi katika makundi machache makubwa ya dawa, na mgawanyiko katika kampuni kuu za dawa ni mpana zaidi kuliko vile takwimu za jumla zinavyoonyesha.<\/p><h3>Je, kasi ya uidhinishaji wa FDA inalinganaje na viwango vya kihistoria mwaka 2026?<\/h3><p>Kituo cha FDA cha Tathmini na Utafiti wa Dawa kiliidhinisha kundi la rekodi la dawa mpya katika 2024-2025, huku tiba za seli na jeni pamoja na onkolojia zikiongoza kwa idadi. Ufafanuzi wa Investopedia kuhusu mienendo ya sekta ya dawa unashughulikia mfumo wa sekta hiyo kwa muktadha wa sasa wa soko, ingawa orodha yake ya kampuni imepitwa na wakati. Mtazamo wa 2026 ni huu: kasi ya udhibiti inasaidia mwendelezo wa uzinduzi mpya, lakini mazungumzo ya bei ya Medicare yamepunguza kwa kiasi kikubwa faida ya uzinduzi katika makundi ya dawa yanayozingatia bei za Marekani.<\/p><h3>Je, wafanyabiashara wa rejareja wanapaswa kupima vipi hatari ya CFD za dawa chini ya kanuni za EU?<\/h3><p>Chini ya mfumo wa uingiliaji kati wa bidhaa wa ESMA kwa CFD za rejareja, leverage ya rejareja ya EU kwa hisa binafsi imewekewa kikomo cha 5:1, ikiwa na ulinzi wa lazima dhidi ya salio hasi na maonyo sanifu ya hatari. Kampuni za dawa hubeba hatari ya matukio yasiyolingana (maamuzi ya FDA, matokeo ya majaribio, matangazo ya mazungumzo ya Medicare) ambayo huongeza kwa kiasi kikubwa mahitaji ya stop-loss ikilinganishwa na hatari ya index pana. Volity, inayopatikana kupitia UBK Markets chini ya leseni ya CySEC 186\/12, inaorodhesha CFD za hisa moja za dawa zenye ukwasi na fedha za wateja zilizotengwa na ufichuzi sanifu wa rejareja.<\/p><hr><h2 class=\"wp-block-heading\" id=\"related-guides\">Miongozo inayohusiana<\/h2><ul><li><a href=\"https:\/\/volity.io\/stocks\/stocks-investing-for-beginners\/\">Uwekezaji wa stocks kwa wanaoanza<\/a><\/li><li><a href=\"https:\/\/volity.io\/stocks\/best-stock-trading-platforms-in-europe-2026\/\">Majukwaa bora ya biashara ya hisa barani Ulaya<\/a><\/li><li><a href=\"https:\/\/volity.io\/stocks\/best-ai-stocks-for-investment\/\">Stocks bora za AI kwa ajili ya uwekezaji<\/a><\/li><li><a href=\"https:\/\/volity.io\/trading-platforms\/best-trading-platforms\/\">Majukwaa bora ya trading<\/a><\/li><li><a href=\"https:\/\/volity.io\/forex\/risk-management\/\">Usimamizi wa hatari<\/a><\/li><\/ul>\r\n\r\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/><div class=\"volity-authority-footer\" data-volity-authority=\"cleanup-2026-06-02\"><h3 class=\"wp-block-heading\">Vyanzo vilivyothibitishwa<\/h3><ul><li><a href=\"https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases\" rel=\"noopener\" target=\"_blank\">Kituo cha idhini na hifadhidata za dawa cha FDA<\/a><\/li><li><a href=\"https:\/\/www.fca.org.uk\/consumers\" rel=\"noopener\" target=\"_blank\">Usimamizi wa FCA kuhusu mienendo ya sekta ya dawa<\/a><\/li><li><a href=\"https:\/\/www.esma.europa.eu\/investor-corner\/product-intervention\" rel=\"noopener\" target=\"_blank\">Mfumo wa ESMA wa uingiliaji kati wa bidhaa kwa CFDs za rejareja<\/a><\/li><\/ul><\/div>\n    <style>\n    .volity-coi {\n        background: #fff;\n        border: 1px solid #c5d8ee;\n        border-radius: 8px;\n        margin: 32px 0;\n        font-family: \"Inter\", sans-serif;\n        font-size: 13.5px;\n        line-height: 1.75;\n        color: #4a4a4a;\n        box-sizing: border-box;\n        width: 100%;\n        overflow: hidden;\n    }\n    .volity-coi .coi-heading {\n        display: block;\n        background: #2c6fad;\n        color: #fff;\n        font-size: 11px;\n        font-weight: 700;\n        letter-spacing: 0.09em;\n        text-transform: uppercase;\n        padding: 9px 22px;\n        margin: 0;\n    }\n    .volity-coi .coi-body { padding: 16px 22px; }\n    .volity-coi .coi-body p { margin: 0 0 10px 0; }\n    .volity-coi .coi-body p:last-child { margin-bottom: 0; }\n    .volity-coi a { color: #2c6fad; text-decoration: underline; }\n    @media(max-width:480px) {\n        .volity-coi .coi-body { padding: 14px 16px; font-size: 13px; }\n        .volity-coi .coi-heading { padding: 8px 16px; }\n    }\n    <\/style>\n    <div class=\"volity-coi\" role=\"note\">\n        <span class=\"coi-heading\">\u24d8 Ufichuzi<\/span>\n        <div class=\"coi-body\"><p>Volity huendesha jukwaa la biashara na pia huchapisha maudhui ya elimu na uchambuzi kuhusu biashara. Maudhui kwenye ukurasa huu ni kwa madhumuni ya elimu pekee na hayapaswi kuchukuliwa kama ushauri wa kifedha. Volity inaweza kunufaika kibiashara wakati wasomaji wanapofungua akaunti za biashara kupitia viungo kwenye tovuti hii.<\/p><p>Maudhui yetu huzalishwa na kupitiwa chini ya <a href=\"https:\/\/volity.io\/sw\/editorial-standards\/\">viwango vya uhariri<\/a> vilivyoandikwa; angalia <a href=\"https:\/\/volity.io\/sw\/editorial-standards\/review-methodology\/\">mbinu yetu ya ulinganisho na mapitio<\/a>.<\/p><\/div>\n    <\/div>\n\r\n","protected":false},"excerpt":{"rendered":"<p>Kuna mdundo wa kimya unaoendelea chini ya uso wa sekta ya dawa, na unazidi kusikika kwa nguvu. Zaidi ya nusu trilioni ya [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":17935,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"custom_schema":"","footnotes":""},"categories":[267],"tags":[],"class_list":["post-53034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cfd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changamoto za Hati Miliki na AI katika Sekta ya Dawa | Volity<\/title>\n<meta name=\"description\" content=\"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/\" \/>\n<meta property=\"og:locale\" content=\"sw_KE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima\" \/>\n<meta property=\"og:description\" content=\"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/\" \/>\n<meta property=\"og:site_name\" content=\"Volity\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61570055360264\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T07:18:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-08T23:50:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1456\" \/>\n\t<meta property=\"og:image:height\" content=\"816\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Alexander Bennett\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:site\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexander Bennett\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\"},\"author\":{\"name\":\"Alexander Bennett\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\"},\"headline\":\"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima\",\"datePublished\":\"2025-08-18T07:18:45+00:00\",\"dateModified\":\"2026-09-08T23:50:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\"},\"wordCount\":3130,\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"articleSection\":[\"CFD\"],\"inLanguage\":\"sw-KE\",\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\",\"name\":\"Changamoto za Hati Miliki na AI katika Sekta ya Dawa | Volity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"datePublished\":\"2025-08-18T07:18:45+00:00\",\"dateModified\":\"2026-09-08T23:50:26+00:00\",\"description\":\"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#breadcrumb\"},\"inLanguage\":\"sw-KE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/\"]}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"ImageObject\",\"inLanguage\":\"sw-KE\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#primaryimage\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Rod-of-Asclepius.webp\",\"width\":1456,\"height\":816,\"caption\":\"Rod of Asclepius\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/volity.io\\\/sw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#website\",\"url\":\"https:\\\/\\\/volity.io\\\/sw\\\/\",\"name\":\"Volity - Effortless, Affordable & Transparent Access To Financial Markets\",\"description\":\"Wepesi kwa Kila Kiwango cha Biashara\",\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#organization\"},\"alternateName\":\"Volity Empowers Financial Inclusion\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/volity.io\\\/sw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sw-KE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#organization\",\"name\":\"Volity\",\"alternateName\":[\"VLT\",\"Volity Group\"],\"url\":\"https:\\\/\\\/volity.io\\\/sw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sw-KE\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"width\":1920,\"height\":1357,\"caption\":\"VOLITY\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61570055360264\",\"https:\\\/\\\/x.com\\\/VolityBeat\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/volitygroup\",\"https:\\\/\\\/www.youtube.com\\\/@VolityYoutube\",\"https:\\\/\\\/www.tiktok.com\\\/@hellovolity\",\"https:\\\/\\\/t.me\\\/volitybeat\",\"https:\\\/\\\/www.trustpilot.com\\\/review\\\/volity.io\"],\"foundingDate\":\"2024\",\"legalName\":\"Volity Capital L.L.C-FZ\",\"address\":{\"@type\":\"PostalAddress\",\"addressCountry\":\"CY\",\"addressLocality\":\"Limassol\",\"streetAddress\":\"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor\",\"postalCode\":\"4003\"},\"contactPoint\":[{\"@type\":\"ContactPoint\",\"contactType\":\"customer support\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"availableLanguage\":[\"English\",\"German\",\"French\",\"Spanish\"],\"areaServed\":[\"EU\",\"GB\",\"Worldwide\"]}],\"knowsAbout\":[\"Forex trading\",\"Contract for difference (CFD) trading\",\"Cryptocurrency trading\",\"Gold and commodities trading\",\"Stock trading\",\"Indices trading\",\"Multi-asset investment platforms\",\"Risk management\"],\"subOrganization\":[{\"@type\":\"Organization\",\"name\":\"Volity Trade Ltd\",\"identifier\":\"Saint Lucia 2024-00059\",\"description\":\"Introducing broker for UBK Markets Ltd\"},{\"@type\":\"Organization\",\"name\":\"Volity Invest Ltd\",\"identifier\":\"Cyprus HE 452984\",\"description\":\"Payment agent\"},{\"@type\":\"Organization\",\"name\":\"Volity Capital L.L.C-FZ\",\"identifier\":\"Dubai trademark 2423068\"}],\"description\":\"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"memberOf\":{\"@type\":\"Organization\",\"name\":\"CySEC, Cyprus Securities and Exchange Commission\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\",\"description\":\"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\\\/12.\"},\"hasCredential\":{\"@type\":\"EducationalOccupationalCredential\",\"name\":\"CySEC CIF licence (via UBK Markets Ltd)\",\"credentialCategory\":\"Regulatory authorisation\",\"recognizedBy\":{\"@type\":\"Organization\",\"name\":\"CySEC\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\"},\"identifier\":\"186\\\/12\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\",\"name\":\"Alexander Bennett\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sw-KE\",\"@id\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"caption\":\"Alexander Bennett\"},\"description\":\"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. His work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/alexanderbennettfm\\\/\",\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\"],\"jobTitle\":\"Financial Analyst & Trading Strategy Expert\",\"givenName\":\"Alexander\",\"familyName\":\"Bennett\",\"url\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"worksFor\":{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/#organization\",\"name\":\"Volity\"},\"knowsAbout\":[\"Forex trading\",\"Cryptocurrency markets\",\"Technical analysis\",\"Risk management\",\"CFD trading\",\"Commodities trading\",\"Trading strategy\",\"TradingView charting\"]},{\"@type\":\"FAQPage\",\"@id\":\"https:\\\/\\\/volity.io\\\/sw\\\/cfd\\\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\\\/#faq\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Je, una pesa nyingi, lakini huna pa kuzitumia?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kwa muktadha wa uwekezaji wa hisa katika sekta mahususi, angalia stock market sectors, blue chip stocks, na fundamental analysis. Mifuko ya makampuni ya dawa ina fedha nyingi, nyingi sana. Kwa uwezo wa zaidi ya $700 billion katika shughuli za M&A uliotayari kutumika, unaweza kudhani kuwa wimbi lijalo la mikataba ya biotech litakuwa likistawi. Isipokuwa... kuna changamoto. Lengo bora la ununuzi - makampuni ya bioteknolojia yenye mapato halisi na siyo tu \\\"majaribio ya kisayansi\\\" - ni adimu. Na mikataba inapotokea, haifanyi kazi kila wakati. Tangu 2018, karibu 80% ya IPO za bioteknolojia zimefeli, na kufuta mabilioni ya mtaji wa wawekezaji na kuwaacha timu za M&A wakiwa na hofu.\"}},{\"@type\":\"Question\",\"name\":\"Basi, nini kinafuata?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Ili kukabiliana na mabadiliko haya, kampuni kubwa za dawa zinapaswa kusawazisha matakwa matatu magumu: Dumisha ubunifu - kupitia utafiti na maendeleo ya ndani pamoja na mikataba ya nje; Linda hazina zao za hataza - bila kusababisha mizozo ya kisheria au kisiasa; Tumia mtaji kwa busara - katika soko ambalo halitoi tena zawadi kwa ajili ya hype. Tathmini za thamani zinaweza kuonekana kuwa nafuu, lakini wawekezaji tahadharini: baadhi ya hisa hizi ziko kwenye mchanga unaotiririka. Mteremko wa hataza si tukio la kalenda tu - ni ramani ya nani aliye hatarini, nani anayetaabika kutafuta ukuaji mpya, na nani anayejenga uthabiti kimya kimya.\"}},{\"@type\":\"Question\",\"name\":\"Je, AI inaweza kuaminiwa katika maamuzi ya utunzaji?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"AI inaweza kurahisisha makaratasi na kubaini makosa. Lakini algoriti zinapoamua matibabu bila usimamizi wa kweli wa binadamu, hali inakuwa hatari. Uwajibikaji unakosekana. Udhibiti unasalia nyuma. Na wagonjwa wamenaswa katika mfumo ambao umeboreshwa zaidi kwa ajili ya akiba kuliko kwa ajili ya afya.\"}},{\"@type\":\"Question\",\"name\":\"Nini Hutokea Unapositisha Ufadhili wa Discovery?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nyufa zinaonekana haraka. Mlipuko wa surua ndio mbaya zaidi katika kipindi cha zaidi ya miaka thelathini. Kusita kupata chanjo kumerudi kwenye kurasa za mbele. Miradi ya bioteknolojia inasuasua, si kwa sababu ya kukosa mawazo, bali kwa sababu ya kukosa ruzuku ya kuyaendeleza. Hata taasisi kubwa za kitaaluma hazijakingwa. Harvard - ndiyo, Harvard hiyo - inachunguzwa na serikali kuhusu jinsi utafiti unaofadhiliwa na serikali unavyogeuzwa kuwa hataza. Ikiwa wadhibiti watachukua hatua kali, daraja kati ya chuo kikuu na sekta ya viwanda linaweza kuyumba, na labda kuvunjika.\"}},{\"@type\":\"Question\",\"name\":\"Kwa nini tunafanya hivi?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Siasa, zaidi. Sayansi haina kundi la wapiga kura, haina ushindi wa haraka. Ni polepole, ya kiufundi, wakati mwingine inakera - na ni ghali. Bajeti zinapopunguzwa, utafiti mara nyingi ndio wa kwanza kuathirika.\"}},{\"@type\":\"Question\",\"name\":\"Je, ukubwa wa changamoto ya hataza ya 2026-2030 ni upi kwa thamani ya dola?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Makubaliano ya sekta yanaweka mapato ya dawa zenye chapa yaliyo hatarini kupoteza upekee katika takriban $200 bilioni katika kipindi cha 2026-2030, huku dawa za kibiolojia zikichukua sehemu kubwa zaidi kuliko katika mizunguko ya awali ya changamoto hii. Kituo cha uidhinishaji wa dawa na hifadhidata cha FDA huchapisha orodha za marejeleo za Orange Book na Purple Book ambazo madawati ya kitaasisi hulinganisha na kalenda za upekee zilizotolewa na kampuni. Mtazamo wa kimuundo kwa wawekezaji ni huu: hatari ya changamoto hii imejikita zaidi katika makundi machache makubwa ya dawa, na mgawanyiko katika kampuni kuu za dawa ni mpana zaidi kuliko vile takwimu za jumla zinavyoonyesha.\"}},{\"@type\":\"Question\",\"name\":\"Je, kasi ya uidhinishaji wa FDA inalinganaje na viwango vya kihistoria mwaka 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Kituo cha FDA cha Tathmini na Utafiti wa Dawa kiliidhinisha kundi la rekodi la dawa mpya katika 2024-2025, huku tiba za seli na jeni pamoja na onkolojia zikiongoza kwa idadi. Ufafanuzi wa Investopedia kuhusu mienendo ya sekta ya dawa unashughulikia mfumo wa sekta hiyo kwa muktadha wa sasa wa soko, ingawa orodha yake ya kampuni imepitwa na wakati. Mtazamo wa 2026 ni huu: kasi ya udhibiti inasaidia mwendelezo wa uzinduzi mpya, lakini mazungumzo ya bei ya Medicare yamepunguza kwa kiasi kikubwa faida ya uzinduzi katika makundi ya dawa yanayozingatia bei za Marekani.\"}},{\"@type\":\"Question\",\"name\":\"Je, wafanyabiashara wa rejareja wanapaswa kupima vipi hatari ya CFD za dawa chini ya kanuni za EU?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Chini ya mfumo wa uingiliaji kati wa bidhaa wa ESMA kwa CFD za rejareja, leverage ya rejareja ya EU kwa hisa binafsi imewekewa kikomo cha 5:1, ikiwa na ulinzi wa lazima dhidi ya salio hasi na maonyo sanifu ya hatari. Kampuni za dawa hubeba hatari ya matukio yasiyolingana (maamuzi ya FDA, matokeo ya majaribio, matangazo ya mazungumzo ya Medicare) ambayo huongeza kwa kiasi kikubwa mahitaji ya stop-loss ikilinganishwa na hatari ya index pana. Volity, inayopatikana kupitia UBK Markets chini ya leseni ya CySEC 186\\\/12, inaorodhesha CFD za hisa moja za dawa zenye ukwasi na fedha za wateja zilizotengwa na ufichuzi sanifu wa rejareja.\"}}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changamoto za Hati Miliki na AI katika Sekta ya Dawa | Volity","description":"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","og_locale":"sw_KE","og_type":"article","og_title":"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima","og_description":"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.","og_url":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","og_site_name":"Volity","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61570055360264","article_published_time":"2025-08-18T07:18:45+00:00","article_modified_time":"2026-09-08T23:50:26+00:00","og_image":[{"width":1456,"height":816,"url":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","type":"image\/webp"}],"author":"Alexander Bennett","twitter_card":"summary_large_image","twitter_creator":"@VolityBeat","twitter_site":"@VolityBeat","twitter_misc":{"Written by":"Alexander Bennett","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#article","isPartOf":{"@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/"},"author":{"name":"Alexander Bennett","@id":"https:\/\/volity.io\/alexander-bennett\/#person"},"headline":"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima","datePublished":"2025-08-18T07:18:45+00:00","dateModified":"2026-09-08T23:50:26+00:00","mainEntityOfPage":{"@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/"},"wordCount":3130,"publisher":{"@id":"https:\/\/volity.io\/sw\/#organization"},"image":{"@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","articleSection":["CFD"],"inLanguage":"sw-KE","speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"WebPage","@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","url":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/","name":"Changamoto za Hati Miliki na AI katika Sekta ya Dawa | Volity","isPartOf":{"@id":"https:\/\/volity.io\/sw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage"},"image":{"@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","datePublished":"2025-08-18T07:18:45+00:00","dateModified":"2026-09-08T23:50:26+00:00","description":"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.","breadcrumb":{"@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#breadcrumb"},"inLanguage":"sw-KE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/"]}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"ImageObject","inLanguage":"sw-KE","@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#primaryimage","url":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2025\/08\/Rod-of-Asclepius.webp","width":1456,"height":816,"caption":"Rod of Asclepius"},{"@type":"BreadcrumbList","@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/volity.io\/sw\/"},{"@type":"ListItem","position":2,"name":"Changamoto za Hati Miliki na Athari za AI katika Sekta ya Dawa na Bima"}]},{"@type":"WebSite","@id":"https:\/\/volity.io\/sw\/#website","url":"https:\/\/volity.io\/sw\/","name":"Volity - Effortless, Affordable & Transparent Access To Financial Markets","description":"Wepesi kwa Kila Kiwango cha Biashara","publisher":{"@id":"https:\/\/volity.io\/sw\/#organization"},"alternateName":"Volity Empowers Financial Inclusion","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/volity.io\/sw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sw-KE"},{"@type":"Organization","@id":"https:\/\/volity.io\/sw\/#organization","name":"Volity","alternateName":["VLT","Volity Group"],"url":"https:\/\/volity.io\/sw\/","logo":{"@type":"ImageObject","inLanguage":"sw-KE","@id":"https:\/\/volity.io\/sw\/#\/schema\/logo\/image\/","url":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","width":1920,"height":1357,"caption":"VOLITY"},"image":{"@id":"https:\/\/volity.io\/sw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61570055360264","https:\/\/x.com\/VolityBeat","https:\/\/www.linkedin.com\/company\/volitygroup","https:\/\/www.youtube.com\/@VolityYoutube","https:\/\/www.tiktok.com\/@hellovolity","https:\/\/t.me\/volitybeat","https:\/\/www.trustpilot.com\/review\/volity.io"],"foundingDate":"2024","legalName":"Volity Capital L.L.C-FZ","address":{"@type":"PostalAddress","addressCountry":"CY","addressLocality":"Limassol","streetAddress":"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor","postalCode":"4003"},"contactPoint":[{"@type":"ContactPoint","contactType":"customer support","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","availableLanguage":["English","German","French","Spanish"],"areaServed":["EU","GB","Worldwide"]}],"knowsAbout":["Forex trading","Contract for difference (CFD) trading","Cryptocurrency trading","Gold and commodities trading","Stock trading","Indices trading","Multi-asset investment platforms","Risk management"],"subOrganization":[{"@type":"Organization","name":"Volity Trade Ltd","identifier":"Saint Lucia 2024-00059","description":"Introducing broker for UBK Markets Ltd"},{"@type":"Organization","name":"Volity Invest Ltd","identifier":"Cyprus HE 452984","description":"Payment agent"},{"@type":"Organization","name":"Volity Capital L.L.C-FZ","identifier":"Dubai trademark 2423068"}],"description":"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","memberOf":{"@type":"Organization","name":"CySEC, Cyprus Securities and Exchange Commission","url":"https:\/\/www.cysec.gov.cy\/","description":"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\/12."},"hasCredential":{"@type":"EducationalOccupationalCredential","name":"CySEC CIF licence (via UBK Markets Ltd)","credentialCategory":"Regulatory authorisation","recognizedBy":{"@type":"Organization","name":"CySEC","url":"https:\/\/www.cysec.gov.cy\/"},"identifier":"186\/12"}},{"@type":"Person","@id":"https:\/\/volity.io\/alexander-bennett\/#person","name":"Alexander Bennett","image":{"@type":"ImageObject","inLanguage":"sw-KE","@id":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","caption":"Alexander Bennett"},"description":"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. His work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\/\/volity.io\/alexander-bennett\/","sameAs":["https:\/\/www.linkedin.com\/in\/alexanderbennettfm\/","https:\/\/volity.io\/alexander-bennett\/"],"jobTitle":"Financial Analyst & Trading Strategy Expert","givenName":"Alexander","familyName":"Bennett","url":"https:\/\/volity.io\/alexander-bennett\/","worksFor":{"@type":"Organization","@id":"https:\/\/volity.io\/#organization","name":"Volity"},"knowsAbout":["Forex trading","Cryptocurrency markets","Technical analysis","Risk management","CFD trading","Commodities trading","Trading strategy","TradingView charting"]},{"@type":"FAQPage","@id":"https:\/\/volity.io\/sw\/cfd\/big-pharma-on-the-edge-patents-pitfalls-and-billions-at-stake\/#faq","mainEntity":[{"@type":"Question","name":"Je, una pesa nyingi, lakini huna pa kuzitumia?","acceptedAnswer":{"@type":"Answer","text":"Kwa muktadha wa uwekezaji wa hisa katika sekta mahususi, angalia stock market sectors, blue chip stocks, na fundamental analysis. Mifuko ya makampuni ya dawa ina fedha nyingi, nyingi sana. Kwa uwezo wa zaidi ya $700 billion katika shughuli za M&A uliotayari kutumika, unaweza kudhani kuwa wimbi lijalo la mikataba ya biotech litakuwa likistawi. Isipokuwa... kuna changamoto. Lengo bora la ununuzi - makampuni ya bioteknolojia yenye mapato halisi na siyo tu \"majaribio ya kisayansi\" - ni adimu. Na mikataba inapotokea, haifanyi kazi kila wakati. Tangu 2018, karibu 80% ya IPO za bioteknolojia zimefeli, na kufuta mabilioni ya mtaji wa wawekezaji na kuwaacha timu za M&A wakiwa na hofu."}},{"@type":"Question","name":"Basi, nini kinafuata?","acceptedAnswer":{"@type":"Answer","text":"Ili kukabiliana na mabadiliko haya, kampuni kubwa za dawa zinapaswa kusawazisha matakwa matatu magumu: Dumisha ubunifu - kupitia utafiti na maendeleo ya ndani pamoja na mikataba ya nje; Linda hazina zao za hataza - bila kusababisha mizozo ya kisheria au kisiasa; Tumia mtaji kwa busara - katika soko ambalo halitoi tena zawadi kwa ajili ya hype. Tathmini za thamani zinaweza kuonekana kuwa nafuu, lakini wawekezaji tahadharini: baadhi ya hisa hizi ziko kwenye mchanga unaotiririka. Mteremko wa hataza si tukio la kalenda tu - ni ramani ya nani aliye hatarini, nani anayetaabika kutafuta ukuaji mpya, na nani anayejenga uthabiti kimya kimya."}},{"@type":"Question","name":"Je, AI inaweza kuaminiwa katika maamuzi ya utunzaji?","acceptedAnswer":{"@type":"Answer","text":"AI inaweza kurahisisha makaratasi na kubaini makosa. Lakini algoriti zinapoamua matibabu bila usimamizi wa kweli wa binadamu, hali inakuwa hatari. Uwajibikaji unakosekana. Udhibiti unasalia nyuma. Na wagonjwa wamenaswa katika mfumo ambao umeboreshwa zaidi kwa ajili ya akiba kuliko kwa ajili ya afya."}},{"@type":"Question","name":"Nini Hutokea Unapositisha Ufadhili wa Discovery?","acceptedAnswer":{"@type":"Answer","text":"Nyufa zinaonekana haraka. Mlipuko wa surua ndio mbaya zaidi katika kipindi cha zaidi ya miaka thelathini. Kusita kupata chanjo kumerudi kwenye kurasa za mbele. Miradi ya bioteknolojia inasuasua, si kwa sababu ya kukosa mawazo, bali kwa sababu ya kukosa ruzuku ya kuyaendeleza. Hata taasisi kubwa za kitaaluma hazijakingwa. Harvard - ndiyo, Harvard hiyo - inachunguzwa na serikali kuhusu jinsi utafiti unaofadhiliwa na serikali unavyogeuzwa kuwa hataza. Ikiwa wadhibiti watachukua hatua kali, daraja kati ya chuo kikuu na sekta ya viwanda linaweza kuyumba, na labda kuvunjika."}},{"@type":"Question","name":"Kwa nini tunafanya hivi?","acceptedAnswer":{"@type":"Answer","text":"Siasa, zaidi. Sayansi haina kundi la wapiga kura, haina ushindi wa haraka. Ni polepole, ya kiufundi, wakati mwingine inakera - na ni ghali. Bajeti zinapopunguzwa, utafiti mara nyingi ndio wa kwanza kuathirika."}},{"@type":"Question","name":"Je, ukubwa wa changamoto ya hataza ya 2026-2030 ni upi kwa thamani ya dola?","acceptedAnswer":{"@type":"Answer","text":"Makubaliano ya sekta yanaweka mapato ya dawa zenye chapa yaliyo hatarini kupoteza upekee katika takriban $200 bilioni katika kipindi cha 2026-2030, huku dawa za kibiolojia zikichukua sehemu kubwa zaidi kuliko katika mizunguko ya awali ya changamoto hii. Kituo cha uidhinishaji wa dawa na hifadhidata cha FDA huchapisha orodha za marejeleo za Orange Book na Purple Book ambazo madawati ya kitaasisi hulinganisha na kalenda za upekee zilizotolewa na kampuni. Mtazamo wa kimuundo kwa wawekezaji ni huu: hatari ya changamoto hii imejikita zaidi katika makundi machache makubwa ya dawa, na mgawanyiko katika kampuni kuu za dawa ni mpana zaidi kuliko vile takwimu za jumla zinavyoonyesha."}},{"@type":"Question","name":"Je, kasi ya uidhinishaji wa FDA inalinganaje na viwango vya kihistoria mwaka 2026?","acceptedAnswer":{"@type":"Answer","text":"Kituo cha FDA cha Tathmini na Utafiti wa Dawa kiliidhinisha kundi la rekodi la dawa mpya katika 2024-2025, huku tiba za seli na jeni pamoja na onkolojia zikiongoza kwa idadi. Ufafanuzi wa Investopedia kuhusu mienendo ya sekta ya dawa unashughulikia mfumo wa sekta hiyo kwa muktadha wa sasa wa soko, ingawa orodha yake ya kampuni imepitwa na wakati. Mtazamo wa 2026 ni huu: kasi ya udhibiti inasaidia mwendelezo wa uzinduzi mpya, lakini mazungumzo ya bei ya Medicare yamepunguza kwa kiasi kikubwa faida ya uzinduzi katika makundi ya dawa yanayozingatia bei za Marekani."}},{"@type":"Question","name":"Je, wafanyabiashara wa rejareja wanapaswa kupima vipi hatari ya CFD za dawa chini ya kanuni za EU?","acceptedAnswer":{"@type":"Answer","text":"Chini ya mfumo wa uingiliaji kati wa bidhaa wa ESMA kwa CFD za rejareja, leverage ya rejareja ya EU kwa hisa binafsi imewekewa kikomo cha 5:1, ikiwa na ulinzi wa lazima dhidi ya salio hasi na maonyo sanifu ya hatari. Kampuni za dawa hubeba hatari ya matukio yasiyolingana (maamuzi ya FDA, matokeo ya majaribio, matangazo ya mazungumzo ya Medicare) ambayo huongeza kwa kiasi kikubwa mahitaji ya stop-loss ikilinganishwa na hatari ya index pana. Volity, inayopatikana kupitia UBK Markets chini ya leseni ya CySEC 186\/12, inaorodhesha CFD za hisa moja za dawa zenye ukwasi na fedha za wateja zilizotengwa na ufichuzi sanifu wa rejareja."}}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}}]}},"yoast_meta":{"yoast_wpseo_title":"Changamoto za Hati Miliki na AI katika Sekta ya Dawa %%sep%% Volity","yoast_wpseo_metadesc":"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.","yoast_wpseo_focuskw":"sekta ya dawa","yoast_wpseo_opengraph-title":"","yoast_wpseo_opengraph-description":"","yoast_wpseo_twitter-title":"","yoast_wpseo_twitter-description":""},"yoast_title":"Changamoto za Hati Miliki na AI katika Sekta ya Dawa %%sep%% Volity","yoast_metadesc":"Jifunze jinsi kuisha kwa hati miliki za dawa na matumizi ya AI katika bima yanavyoathiri soko la hisa na mikakati ya uwekezaji katika sekta ya afya.","_links":{"self":[{"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/posts\/53034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/comments?post=53034"}],"version-history":[{"count":1,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/posts\/53034\/revisions"}],"predecessor-version":[{"id":53061,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/posts\/53034\/revisions\/53061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/media\/17935"}],"wp:attachment":[{"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/media?parent=53034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/categories?post=53034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/volity.io\/sw\/wp-json\/wp\/v2\/tags?post=53034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}